Lumiere Charity

Tuesday, December 30, 2014

Candle has been lit in Remembrance of Youth in Desperation

A CANDLE HAS BEEN LIT IN REMEMBRANCE OF YOUTH IN DESPERATION.
There are many young people working years and saving to study towards a brighter future.
Yet due to various circumstances, they struggle to manage to pay - despite years of working, saving and holding down jobs outside study hours - to pay tuition costs.

Lumiere Charity is beginning a series of blog posts where students in difficulties can speak about their personal plight.
One such student is Haince Pen.
Haince comes from India, and after years of working and saving is studying at Rochester Institute of Technology.
A loan was received from the bank, his parents mortgaged their house as assurance.
At the end of this semester, despite working at a job during his time off from study, his savings and his parents' dedicated loan, he will be short five thousand dollars for his next semester.
Why not pledge one to five dollars to help Haince continue his dream; to study towards a brighter future?

Perhaps Divine Providence led you

to read these words.

In the spirit of Lumiere, is there

anything you can do to help?

To donate directly to Haince's tuition,

please click on this link;

http://www.youcaring.com/tuition-fundraiser/help-haince-pay-the-college-tuition-fees/283385

Friday, December 26, 2014

Lumiere Remembers Journalists Killed In the Line of Duty

A CANDLE HAS BEEN LIT IN REMEMBRANCE OF JOURNALISTS KILLED

IN THE LINE OF DUTY IN 2014.

Dedicated men and women living lives of bravery and truth,

bringing news to our attention, daily place their lives on the line.

Lumiere remembers all those who have lost their lives

this past year, and their families and friends.

http://www.nytimes.com/aponline/2014/12/23/us/ap-us-journalists-killed-in-2014.html?_r=0

http://lumierecharity.blogspot.co.uk/2012/12/lumiere-charity-remembers-journalists.html

With thanks to nytimes.com

New Vaccine Candidate to Prevent Chikungunya has been Developed, Alleged News

ACCORDING TO THE TIMES OF INDIA 15 AUGUST 2014, NEW VACCINE CANDIDATE TO PREVENT CHIKUNGUNYA HAS REPORTEDLY BEEN DEVELOPED.
In a breakthrough, Scientists have have developed a new vaccine candidate to provide protection from the mosquito-borne viral illness Chikungunya. The experimental vaccine allegedly elicited neutralising antibodies in all 25 adult volunteers who participated in an early-stage clinical trial conducted by Researchers at the National Institute of Allergy and Infectious Diseases (NIAID). (1)

The Lancet reports on a chikungunya trial
The Lancet gave background to safety and tolerability of chikungunya virus-like particle vaccine in healthy adults; a phase 1 dose-escalation trial.
Chikungunya virus - a mosquito-borne alphavirus - is endemic in Africa, South and Southeast Asia, and has emerged in the Caribbean. No drugs or vaccines are available for treatment or prevention. The aim of the trial was to assess the safety, tolerability and immunogenicity of a new candidate vaccine.,
Methods; VRC 311 was a phase 1, dose-escalation open-label clinical trial of a virus-like particle (VLP) chikungunya virus vaccine VRC-CHKVLP059-00-VP. Participants were assigned to sequential dose level groups [see document.] (2)
The findings were fully documented. The trial is registerd with ClinicalTrials.gov (3) NCT01489358.
[4]
The interpretation is that the chikungunya VLP vaccine was immunogenic, safe and well-tolerated. The Lancet considered the study they discussed as representing an important step in vaccine development to combat this rapidly emerging pathogen.
The Lancet recommended that further studies should be done in a larger number of participants and in more diverse populations. (2)

(1) New vaccine to prevent chikungunga developed
h ttp://timesofindia.indiatimes.com/home/science/New-vaccine-to-prevent-chikungunya-developed/articleshow/40309932.cms

(2) Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults; a phase 1 dose-escalation trial
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736%2814%2961185-5.pdf

(3) https://clinicaltrials.gov/

[4] NCT01489358.
https://clinicaltrials.gov/show/NCT01489358

Chikungunya virus Infects more than 1 Million in Americas
http://www.voanews.com/content/chikungunya-virus-has-infected-more-than-1-million-in-americas/2570840.html

*Disclaimer; Please note that the information on this Blog Post is not meant to replace the original information imparted from the resources from which the Post is drawn. The information given above is intended to disseminate information of relevance and interest only. Please check sources to verify that information given above was correctly quoted; No responsibility rests on the writer of the blog posts re same